Skip to main content

Advertisement

SpringerLink
Log in

Serum CD44 levels and overall survival in patients with HER2-positive breast cancer

  • Epidemiology
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

CD44 is an adhesion molecule involved in tumor cell invasion and metastasis. The function of CD44 in breast cancer is not understood completely, or is its role as a predictive or prognostic factor. In this study, we tested for the hypothesis that the concentration of soluble CD44 (sCD44) in serum is correlated with clinicopathological factors, especially HER2, and survival in patients with breast cancer. We retrospectively identified 110 patients with breast cancer who had been treated at The University of Texas MD Anderson Cancer Center (MDACC) from September 2001 to May 2004. Sera were collected before definitive surgery in patients with stage I or II breast cancer, before initiation of neoadjuvant chemotherapy (if indicated) for patients with stage I–III breast cancer, and before initiation of systemic therapy in patients with stage IV breast cancer. sCD44 levels were determined using an enzyme-linked immunosorbent assay. The median age at diagnosis was 51 years (range, 28.6–87.1 years). sCD44 concentration was correlated with tumor stage (P = 0.0308). sCD44 serum concentration did not predict pathological response in patients treated with neoadjuvant chemotherapy. Among patients with distant metastases, sCD44 levels were significantly higher in patients with liver involvement than in patients with metastases at other sites. The overall survival rate did not differ between patients with high sCD44 concentration and patients with low sCD44 concentration. However, sCD44 concentration was a significant predictor of overall survival for patients with HER2-positive breast cancer, while no difference in overall survival rates was observed in patients with HER2-negative breast cancer. To the best of our knowledge, this is the first study to show an association between circulating sCD44 levels and survival in HER2-positive breast cancer patients. Our results suggest a role for sCD44 as a prognostic marker. Furthermore, sCD44 level may offer a new clinical therapeutic target in HER2-positive breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988

    Article  PubMed  CAS  Google Scholar 

  2. Stamenkovic I, Aruffo A, Amiot M, Seed B (1991) The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronate-bearing cells. EMBO J 10:343–348

    PubMed  CAS  Google Scholar 

  3. Nagano O, Saya H (2004) Mechanism and biological significance of CD44 cleavage. Cancer Sci 95:930–935

    Article  PubMed  CAS  Google Scholar 

  4. Okamoto I, Tsuiki H, Kenyon LC et al (2002) Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. Am J Pathol 160:441–447

    Article  PubMed  CAS  Google Scholar 

  5. Guo YJ, Liu G, Wang X et al (1994) Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54:422–426

    PubMed  CAS  Google Scholar 

  6. Lackner C, Moser R, Bauernhofer T et al (1998) Soluble CD44 v5 and v6 in serum of patients with breast cancer. Correlation with expression of CD44 v5 and v6 variants in primary tumors and location of distant metastasis. Breast Cancer Res Treat 47:29–40

    Article  PubMed  CAS  Google Scholar 

  7. Molica S, Vitelli G, Levato D, Giannarelli D, Gandolfo GM (2001) Elevated serum levels of soluble CD44 can identify a subgroup of patients with early B-cell chronic lymphocytic leukemia who are at high risk of disease progression. Cancer 92:713–719

    Article  PubMed  CAS  Google Scholar 

  8. Niitsu N, Iijima K (2002) High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin’s lymphoma. Leuk Res 26:241–248

    Article  PubMed  CAS  Google Scholar 

  9. Guriec N, Marcellin L, Gairard B et al (1996) CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin Exp Metastasis 14:434–439

    Article  PubMed  CAS  Google Scholar 

  10. Lockhart MS, Waldner C, Mongini C et al (1999) Evaluation of soluble CD44 in patients with breast and colorectal carcinomas and non-Hodgkin’s lymphoma. Oncol Rep 6:1129–1133

    PubMed  CAS  Google Scholar 

  11. Sanchez Lockhart M, Hajos SE, Basilio FM, Mongini C, Alvarez E (2001) Splice variant expression of CD44 in patients with breast and ovarian cancer. Oncol Rep 8:145–151

    PubMed  CAS  Google Scholar 

  12. Mayer S, zur Hausen A, Watermann DO et al (2008) Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients. J Cancer Res Clin Oncol 134:1229–1235

    Article  PubMed  CAS  Google Scholar 

  13. Sheen-Chen SM, Chen WJ, Eng HL, Sheen CC, Chou FF, Cheng YF (1999) Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer. Cancer Invest 17:581–585

    Article  PubMed  CAS  Google Scholar 

  14. Amirghofran Z, Jalali SA, Hosseini SV, Vasei M, Sabayan B, Ghaderi A (2008) Evaluation of CD44 and CD44v6 in colorectal carcinoma patients: soluble forms in relation to tumor tissue expression and metastasis. J Gastrointest Cancer 39:73–78

    Article  PubMed  CAS  Google Scholar 

  15. Woodman AC, Sugiyama M, Yoshida K et al (1996) Analysis of anomalous CD44 gene expression in human breast, bladder, and colon cancer and correlation of observed mRNA and protein isoforms. Am J Pathol 149:1519–1530

    PubMed  CAS  Google Scholar 

  16. Bhatavdekar JM, Patel DD, Shah NG et al (2000) Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Ann Surg Oncol 7:305–311

    Article  PubMed  CAS  Google Scholar 

  17. Yamane N, Tsujitani S, Makino M, Maeta M, Kaibara N (1999) Soluble CD44 variant 6 as a prognostic indicator in patients with colorectal cancer. Oncology 56:232–238

    Article  PubMed  CAS  Google Scholar 

  18. Kokko LL, Hurme S, Maula SM et al (2011) Significance of site-specific prognosis of cancer stem cell marker CD44 in head and neck squamous-cell carcinoma. Oral Oncol 47(6):510–516

    Article  PubMed  CAS  Google Scholar 

  19. Esteva FJ, Hortobagyi GN, Sahin AA, Smith TL, Chin DM, Liang SY, Pusztai L, Buzdar AU, Bacus SS (2001) Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 7(3):171–177

    Google Scholar 

  20. Korkaya H, Paulson A, Iovino F, Wicha MS (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27:6120–6130

    Article  PubMed  CAS  Google Scholar 

  21. Li X, Lewis MT, Huang J et al (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100:672–679

    Article  PubMed  CAS  Google Scholar 

  22. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235

    Article  PubMed  Google Scholar 

  23. Gunthert U, Hofmann M, Rudy W et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65:13–24

    Article  PubMed  CAS  Google Scholar 

  24. Seiter S, Arch R, Reber S et al (1993) Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177:443–455

    Article  PubMed  CAS  Google Scholar 

  25. Masson D, Denis MG, Denis M et al (1999) Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer. Br J Cancer 80:1995–2000

    Article  PubMed  CAS  Google Scholar 

  26. Kopp R, Classen S, Wolf H, Gholam P, Possinger K, Wilmanns W (2001) Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer. Anticancer Res 21:2995–3000

    PubMed  CAS  Google Scholar 

  27. Zhou J, Nagarkatti PS, Zhong Y, Creek K, Zhang J, Nagarkatti M (2010) Unique SNP in CD44 intron 1 and its role in breast cancer development. Anticancer Res 30:1263–1272

    PubMed  Google Scholar 

  28. Weg-Remers S, Hildebrandt U, Feifel G, Moser C, Zeitz M, Stallmach A (1998) Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6. Am J Gastroenterol 93:790–794

    Article  PubMed  CAS  Google Scholar 

  29. Zalewski B (2004) Levels of v5 and v6 CD44 splice variants in serum of patients with colorectal cancer are not correlated with pT stage, histopathological grade of malignancy and clinical features. World J Gastroenterol 10:583–585

    PubMed  CAS  Google Scholar 

  30. Gotte M, Yip GW (2006) Heparanase, hyaluronan, and CD44 in cancers: a breast carcinoma perspective. Cancer Res 66:10233–10237

    Article  PubMed  Google Scholar 

  31. Chang SM, Xing RD, Zhang FM, Duan YQ (2009) Serum soluble CD44v6 levels in patients with oral and maxillofacial malignancy. Oral Dis 15:570–572

    Article  PubMed  CAS  Google Scholar 

  32. Kim HJ, Kim MJ, Ahn SH et al (2011) Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. Breast 20:78–85

    Article  PubMed  Google Scholar 

  33. Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N (1998) Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer 83:1094–1101

    Article  PubMed  CAS  Google Scholar 

  34. Klingbeil P, Natrajan R, Everitt G et al (2010) CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res Treat 120:95–109

    Article  PubMed  CAS  Google Scholar 

  35. Shah NG, Trivedi TI, Vora HH et al (2010) CD44v6 expression in primary breast carcinoma in western India: a pilot clinicopathologic study. Tumori 96:971–977

    PubMed  CAS  Google Scholar 

  36. Berner HS, Suo Z, Risberg B, Villman K, Karlsson MG, Nesland JM (2003) Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 42:546–554

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was funded in part by the Breast Cancer Research Foundation. MDACC is supported by the National Institutes of Health through grant CA16672. The authors thank Kathryn B. Carnes and Sarah Bronson from the Department of Scientific Publications at MDACC for their assistance.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA

    Jong-Min Baek, Quanri Jin, Delphine R. Boulbes & Francisco J. Esteva

  2. Department of Biostatistics, Unit 1411, T. Boone Pickens Academic Tower, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA

    Joe Ensor

Authors
  1. Jong-Min Baek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Quanri Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joe Ensor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Delphine R. Boulbes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francisco J. Esteva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francisco J. Esteva.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baek, JM., Jin, Q., Ensor, J. et al. Serum CD44 levels and overall survival in patients with HER2-positive breast cancer. Breast Cancer Res Treat 130, 1029–1036 (2011). https://doi.org/10.1007/s10549-011-1691-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1691-z

Keywords

Search

Navigation